Indomethacin works well for acute gout flares and has been a go-to treatment for decades, but it is no longer considered superior to other options. Head-to-head trials consistently show that alternatives like prednisolone and other anti-inflammatory drugs relieve gout pain just as effectively, often with fewer side effects. The drug remains a legitimate choice, but the old notion that indomethacin is the gold-standard gout treatment has not held up under modern scrutiny.
How Well Does It Actually Relieve Gout Pain?
Indomethacin reliably reduces the pain, swelling, and redness of an acute gout attack. In randomized trials comparing it directly to oral prednisolone (a corticosteroid), pain scores dropped at similar rates in both groups over two weeks. One trial tracking patients from the emergency department through follow-up found that pain scores during activity declined by roughly the same amount per day with indomethacin and prednisolone, and both exceeded the threshold for clinically meaningful improvement.1Caring for the Ages. Oral Prednisolone vs. Indomethacin for Acute Gout A separate three-arm trial comparing indomethacin, prednisolone, and etoricoxib (a newer anti-inflammatory) found that all three were equally effective at reducing pain, tenderness, redness, and improving joint movement over four days.2PubMed Central. Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial
So the short version is that indomethacin does what you need it to do during a gout flare: it brings down inflammation and eases pain within days. The problem is not that it fails. The problem is that it does not outperform safer or cheaper alternatives, which raises the question of why you would choose it over them.
Why Indomethacin Was Once the Automatic Choice
For a long time, many textbooks and practitioners treated indomethacin as essentially synonymous with gout treatment. This reputation developed partly because indomethacin was one of the first potent anti-inflammatory drugs available and was studied early in gout trials. It became a default through familiarity rather than through evidence that it was better than other options. Older prescribing habits die hard, and some clinicians still reach for indomethacin reflexively when a patient presents with a hot, swollen joint.
Modern guidelines have moved away from that reflexive preference. The evidence base now includes multiple randomized trials showing equivalent efficacy among several anti-inflammatory drugs, and treatment recommendations from professional rheumatology organizations no longer single out indomethacin as the preferred agent within its class. It is one option among many, and often not the best-tolerated one.
The Side Effect Problem
This is where indomethacin’s case weakens considerably. While it matches other drugs in effectiveness, it consistently produces more adverse effects. In the three-arm trial mentioned above, the total number of adverse events in the indomethacin group was significantly higher than in the prednisolone or etoricoxib groups.2PubMed Central. Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial In another trial, about one in five patients taking indomethacin reported minor adverse events compared to roughly one in sixteen on prednisolone, and seven patients in the indomethacin arm discontinued treatment because of side effects versus just one in the prednisolone arm. Those side effects included abdominal pain, dizziness, and lethargy.1Caring for the Ages. Oral Prednisolone vs. Indomethacin for Acute Gout
The gastrointestinal effects are the most well-known concern. Indomethacin, like other traditional anti-inflammatory drugs, can damage the stomach lining. Animal studies examining stomach tissue after indomethacin exposure have found significant structural damage, including fragmented tissue fibers, reduced cell differentiation, and detachment of the stomach’s protective lining, along with inflammatory cell infiltration.3PubMed Central. Chitosan-Stabilized Lipid Vesicles with Indomethacin for Modified Release with Prolonged Analgesic Effect: Biocompatibility, Pharmacokinetics and Organ Protection Efficacy In practice, this translates to stomach pain, nausea, and in more serious cases, bleeding or ulceration in people taking the drug. Anyone with a history of stomach ulcers or gastrointestinal bleeding should be especially cautious.
Some patients also worry about drowsiness or impaired coordination with indomethacin, since dizziness and headache are listed among its known side effects. Interestingly, a controlled study looking specifically at whether indomethacin impairs motor coordination and reaction time found no measurable differences between indomethacin and placebo on those outcomes. The researchers concluded that patients experiencing central nervous system side effects may not need to be warned away from activities like driving, though individual responses vary.4PubMed Central. CNS effects of indomethacin: should patients be cautioned about decreased mental alertness and motor coordination? That said, if you personally feel dizzy or foggy on the drug, trust your body over the population-level finding.
Drug Interactions Worth Knowing About
Indomethacin’s interaction profile matters, especially because gout patients often take other medications. Two interactions stand out as particularly important.
If you take warfarin (a blood thinner), adding indomethacin is risky. A documented case involved a patient who developed spontaneous bruising and blood in the urine while on both drugs simultaneously. The concern is twofold: indomethacin can amplify warfarin’s blood-thinning effect and independently raises the risk of gastrointestinal bleeding. Anyone on warfarin who needs indomethacin should have their clotting time monitored closely.5PubMed. Adverse interaction between warfarin and indomethacin
Lithium, used for bipolar disorder, is another major interaction. Indomethacin reduces how efficiently the kidneys clear lithium, decreasing lithium elimination by about a quarter and raising blood lithium levels by roughly 40 percent. Since lithium has a narrow therapeutic range, that kind of increase can push levels into the toxic zone. Frequent monitoring of lithium levels is considered essential if both drugs are used together.6PubMed. Indomethacin but not aspirin increases plasma lithium ion levels
Beyond these specific interactions, indomethacin shares the general concerns of its drug class when it comes to kidney function and blood pressure. It can reduce kidney blood flow, which is a particular concern for gout patients since many already have some degree of kidney impairment. And like other drugs in its class, it can raise blood pressure and counteract the effects of blood pressure medications. If you are managing gout alongside hypertension or kidney disease, these are conversations worth having with your doctor before starting indomethacin.
How Indomethacin Is Typically Dosed for a Gout Flare
The standard dosing for an acute gout attack is 50 mg taken three times daily.7Swiss Medical Weekly. Guidelines for the treatment of gout: a Swiss perspective Guidelines stress that treatment should begin as soon as the flare starts and continue until the attack fully resolves. The sooner you take it after symptoms begin, the more effectively it tends to work. Waiting a day or two into a flare before starting treatment generally means a slower and less complete response.
In clinical trials studying gout treatment strategies, indomethacin at this dose has been used for courses lasting around 10 days, often alongside colchicine as a bridge while starting long-term urate-lowering therapy.8The American Journal of Medicine. Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial In practice, many clinicians will taper the dose down after the first few days once the worst of the inflammation subsides, aiming to minimize the cumulative side-effect burden. The principle across all guidelines is the same: use the maximum effective dose early, then scale back as the flare resolves.
Where Indomethacin Fits in Current Treatment Guidelines
The 2020 American College of Rheumatology guideline for gout management does not give indomethacin any special status among anti-inflammatory drugs for flare treatment. The guideline groups it alongside other options, with the broader recommendation being to use whichever anti-inflammatory drug is appropriate for the patient’s other health conditions and medication profile.9PubMed Central. 2020 American College of Rheumatology Guideline for the Management of Gout For long-term management, the guideline strongly recommends allopurinol as the preferred first-line urate-lowering therapy for preventing future flares, which is a separate issue from treating acute attacks but worth knowing since many patients confuse flare treatment with prevention.
International guidelines generally align on this point. A Swiss review of gout treatment recommendations noted that several anti-inflammatory drugs have been studied in randomized trials for acute gout, including naproxen, indomethacin, celecoxib, and etoricoxib, and that guidelines recommend fast-acting options at maximum doses started as early as possible.7Swiss Medical Weekly. Guidelines for the treatment of gout: a Swiss perspective The consistent theme is that the class of drug matters more than the specific agent. If you tolerate indomethacin well and have no contraindications, it remains a valid choice. But if you have never tried it before and your doctor suggests naproxen or a corticosteroid instead, there is no evidence-based reason to insist on indomethacin.
Prednisolone as an Alternative and the Cost Question
The most direct competitor for indomethacin in gout flare treatment is oral prednisolone, a corticosteroid. As noted earlier, the two drugs produce equivalent pain relief. But prednisolone has some practical advantages that extend beyond side effects. Prednisolone is a particularly appealing option for patients who cannot tolerate anti-inflammatory drugs due to kidney disease, stomach problems, or blood thinner use, since corticosteroids sidestep those specific risks.
There is also a cost difference. A study from an emergency department setting found that using prednisolone instead of indomethacin saved the equivalent of roughly US$158 per patient treated. The savings came partly from fewer emergency department resources needed and partly from reduced hospital admissions. Six patients in the indomethacin group were admitted for serious adverse effects, each at a cost exceeding US$1,600, while the prednisolone group avoided those admissions entirely.10PubMed. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis For healthcare systems managing large numbers of gout patients, those economics add up. For individual patients, the practical takeaway is that prednisolone is typically cheaper and associated with fewer complications that lead to additional medical visits.
That said, corticosteroids are not without their own drawbacks. Short courses are generally well tolerated, but they can raise blood sugar, which is relevant for people with diabetes. They can also cause mood changes and sleep disruption. Prednisolone might be slightly more effective at reducing swelling compared to indomethacin, as one trial found a statistically significant difference favoring prednisolone on that specific outcome, even while the two drugs performed similarly on every other measure.2PubMed Central. Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial
When Indomethacin Still Makes Sense
Despite its drawbacks, indomethacin is not a bad drug. It has a clear role for certain patients. If you have used it before, know you tolerate it well, and have no kidney disease, stomach history, or concerning drug interactions, there is no compelling reason to switch. Familiarity counts for something in medication adherence. A treatment you know works for your body and that you will actually take on schedule is better than a theoretically superior option that sits in the medicine cabinet.
Indomethacin may also be a reasonable choice when corticosteroids are not an option, such as for patients with poorly controlled diabetes where even a short corticosteroid course could cause problematic blood sugar spikes. In some healthcare settings, it remains more readily available than certain newer anti-inflammatory drugs. And for patients who have had unsatisfactory responses to naproxen or ibuprofen in past flares, trying indomethacin’s somewhat different pharmacological profile is a legitimate clinical decision.
The Future of Anti-Inflammatory Delivery for Gout
Researchers are exploring ways to preserve indomethacin’s anti-inflammatory power while reducing its toll on the stomach and other organs. One line of investigation involves packaging indomethacin in nanoparticle delivery systems that could target inflamed joints more directly. An experimental platform combining indomethacin with uricase (an enzyme that breaks down uric acid) showed stronger anti-inflammatory effects in a rat model of gout than either component alone, reducing joint swelling and synovial inflammation more effectively.11PubMed Central. Co-delivery of indomethacin and uricase as a new strategy for inflammatory diseases associated with high uric acid Separately, lipid-based carrier systems designed to release indomethacin gradually have shown promise in animal studies, preserving normal stomach tissue structure while still delivering the drug’s analgesic effects over a prolonged period.3PubMed Central. Chitosan-Stabilized Lipid Vesicles with Indomethacin for Modified Release with Prolonged Analgesic Effect: Biocompatibility, Pharmacokinetics and Organ Protection Efficacy
These are early-stage findings, far from clinical use. But they reflect genuine interest in solving the core trade-off that has always defined indomethacin in gout treatment: the drug works, but its side effects limit who can safely use it and for how long. If future formulations can decouple the anti-inflammatory benefit from the gastrointestinal damage, indomethacin’s place in gout management could shift again. For now, the drug remains what decades of evidence say it is: effective, familiar, and rougher on the body than the alternatives.